Cytek Biosciences Inc

NASDAQ:CTKB USA Medical Devices
Market Cap
$557.91 Million
Market Cap Rank
#10866 Global
#4943 in USA
Share Price
$4.34
Change (1 day)
+2.12%
52-Week Range
$2.42 - $5.88
All Time High
$27.93
About

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more

Cytek Biosciences Inc - Asset Resilience Ratio

Latest as of December 2025: 36.98%

Cytek Biosciences Inc (CTKB) has an Asset Resilience Ratio of 36.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$170.68 Million
Cash + Short-term Investments
Total Assets
$461.54 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Cytek Biosciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Cytek Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $170.68 Million 36.98%
Total Liquid Assets $170.68 Million 36.98%

Asset Resilience Insights

  • Very High Liquidity: Cytek Biosciences Inc maintains exceptional liquid asset reserves at 36.98% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Cytek Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare Cytek Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
FluroTech Ltd
OTCQB:FLURF
Medical Devices 0.00%
DRGEM Corporation
KQ:263690
Medical Devices 0.50%
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
Medical Devices 0.01%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.26%
Double Medical Technology Inc
SHE:002901
Medical Devices 7.79%
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
Medical Devices 6.64%
Shinhung
KO:004080
Medical Devices 4.17%
UMediC Group Berhad
KLSE:0256
Medical Devices 1.48%

Annual Asset Resilience Ratio for Cytek Biosciences Inc (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Cytek Biosciences Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 36.98% $170.68 Million $461.54 Million +1.11pp
2024-12-31 35.86% $179.15 Million $499.50 Million +16.63pp
2023-12-31 19.24% $95.11 Million $494.46 Million +10.66pp
2022-12-31 8.58% $44.55 Million $519.48 Million --
2021-12-31 0.00% $0.00 $463.31 Million --
pp = percentage points